FDA approves first cancer treatment for any solid tumor with a specific genetic feature

May 23, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Pembrolizumab is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that … (leggi tutto)